$AKLI News
Last published 2y ago
- 2y agoAKLIBMYPRTCVORPureTech Health plc – Half-Year ReportBusiness WireStrong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback
- 2y agoAKLIVirtual Therapeutics Announces Results of Tender Offer to Acquire Akili InteractiveBusiness WireVirtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games ("Virtual Therapeutics"), today announced that it has successfully completed the tender offer commenced on June
- 2y agoAKLIAkili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video GameBusiness WireClinically proven to improve attention function, EndeavorOTCⓇ is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD Akili, Inc. (NASDAQ:AKLI), a leading digital
- 2y agoAGRAKLICALTSGEKuehn Law Encourages CALT, AKLI, AGR, and SGE Investors to Contact Law FirmGlobeNewswireNEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoAKLIPRTCPureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health CompanyBusiness WireAkili to operate as wholly owned subsidiary of Virtual Therapeutics PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today
- 2y agoAKLIAkili Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness WireCompany announces full voluntary prepayment of debt and termination of Amended & Restated Loan and Security Agreement with Silicon Valley Bank Following recent restructuring, focusing efforts primarily on
- 2y agoAKLIAkili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial ResultsBusiness WireShionogi amendment provides Akili with near-term cash payments and cancellation of debt obligation Company announces exploration of strategic alternatives and associated workforce reduction Company to release first
- 2y agoAKLIBMYKRTXPRTC+1PureTech Announces Annual Results for Year Ended December 31, 2023Business WireSignificant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for Seaport, and the $14
- 2y agoAKLIAkili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateBusiness WireFY 2023 total revenues of $1.7M, a 420% increase over FY 2022 as EndeavorOTCⓇ gained traction in the market following June 2023 product release Reports fourth quarter 2023 total revenues of $749 thousand, representing
- 2y agoAKLIPRTCPureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in JapanBusiness WireJapanese Product Now Under Review for Nationwide Marketing Approval PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to
- 2y agoAKLIAkili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in JapanBusiness WireJapanese Product Now Under Review for Nationwide Marketing Approval Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's
- 2y agoAKLIAkili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance UpdatesBusiness WirePlans to disclose Q4/FY 2023 financial results on February 29, 2024; CEO Matthew Franklin to participate in fireside chat at TD Cowen's 44th Annual Healthcare Conference on March 4, 2024 Appointed John Spinale to
- 2y agoAKLIKRTXPRTCVORPureTech Year End Update and Outlook for 2024Business WireStrong strategic and clinical progress in 2023, with multiple catalysts expected in 2024 Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline Robust balance sheet position
- 2y agoAKLIEndeavorRxⓇ, World's First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17Business WireAkili's Clinically Proven Digital Medicine Now Authorized for Children 8-17, Opening Option to More Patients as Ongoing Stimulant Shortage Persists Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today
- 3y agoAKLIAkili Reports Third Quarter 2023 Financial Results and Provides Business UpdateBusiness WireReports third quarter total revenues of $702 thousand, representing more than 5x growth over the second quarter of 2023, and positive gross margins of ~60% in the quarter Company has filed EndeavorOTC with FDA as an
- 3y agoAKLIAkili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ETBusiness WireAkili, Inc. (NASDAQ:AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the third quarter of 2023 on Thursday, November 9, 2023, at 4:30
- 3y agoAKLIKRTXPRTCPureTech to Present at Two Upcoming Investor ConferencesBusiness WireCompany summarizes third quarter progress across its Wholly Owned Pipeline and Founded Entities PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage
- 3y agoAKLIEmployees with ADHD Aren't Reaching Their Full Potential at Work, Akili Study FindsBusiness WireRespondents struggle with routine tasks, career setbacks, and limited treatment options; meanwhile, managers feel unprepared to provide support Akili, Inc. (NASDAQ:AKLI), the leading digital medicine company behind
- 3y agoAKLIAkili Announces Leadership TransitionBusiness WireCo-founder and CEO Eddie Martucci, Ph.D. transitions to role of Board chair; Matt Franklin, president and chief operating officer of Akili, appointed president and chief executive officer Akili, Inc. (NASDAQ:AKLI), a
- 3y agoAKLIAkili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHDBusiness WireClinical trial data show that 83% of adults with ADHD experienced improved focus, and 73% reported improvement in quality of life after EndeavorOTC treatment Available nationwide without a prescription, EndeavorOTC
- 3y agoAKLIAkili Announces Business Transformation, Focusing on Non-prescription ModelBusiness WireNon-prescription model will increase patient access to clinically-validated non-drug treatments and reduce Akili's reliance on intermediaries Continued growth in consumer demand and engagement for EndeavorOTC™
- 3y agoAKLITech Startup Founders Unite in Chicago for Candid Conversation and Insights at the Founders Roundtable Event hosted by LeadrProPR NewswireCHICAGO, Sept. 12, 2023 /PRNewswire/ -- Calling all Founders, entrepreneurs, and visionaries! LeadrPro invites you to join us at the upcoming Founders Roundtable event in downtown Chicago, a unique opportunity to connect
- 3y agoAKLIKRTXPRTCVORPureTech Health plc – Half-Year ReportBusiness WireStrong progression of PureTech's Wholly Owned Pipeline, with three clinical-stage therapeutic candidates being evaluated across four clinical trials to address large patient needs in pulmonary, oncology and CNS
- 3y agoAKLIAkili, Inc. (AKLI) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoAKLIAkili Reports Second Quarter 2023 Financial Results and Provides Business UpdateBusiness WireEndeavorRxⓇ prescriptions in pediatric ADHD market grew 27% in Q2 2023 over Q1 2023 Company is preparing FDA submission for EndeavorOTCTM as over-the-counter treatment, following its June 2023 product release in the
- 3y agoAKLIAkili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ETBusiness WireAkili, Inc. (NASDAQ:AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the second quarter of 2023 on Thursday, August 10, 2023, at 4:30
- 3y agoAKLIAkili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHDBusiness WireAmid growing mental health crisis, the product release enables immediate access to non-drug treatment option as Akili prepares FDA submission Available nationwide without a prescription, clinical data shows
- 3y agoAKLIAkili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych CongressBusiness WireNearly two-thirds of adolescents saw clinically meaningful improvement in attention following treatment Improvements were nearly three times as large as those in the pivotal trial that supported EndeavorRx's FDA
- 3y agoAKLIAkili Reports First Quarter 2023 Financial Results and Provides Business UpdateBusiness WireEndeavorRxⓇ prescriptions for children with ADHD increased 32% in Q1 2023 over Q4 2022 Pivotal study in adults with ADHD showed significant improvements in attention and clinical outcomes, exceeding those observed in
- 3y agoAKLIPRTCPureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili's EndeavorRx® Video Game-Based TherapeuticBusiness WireAttention improved in more than 80 percent of adults with ADHD, and over one-third of participants no longer exhibited an attention deficit following treatment Improvements in attention were nearly seven times larger
- 3y agoAKLIAdults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili's EndeavorRx® Video Game-Based TherapeuticBusiness WireAttention improved in more than 80 percent of adults with ADHD, and over one-third of participants no longer exhibited an attention deficit following treatment Improvements in attention were nearly seven times larger
- 3y agoAKLIBIIBKRTXPRTC+1PureTech Announces Annual Results for Year Ended December 31, 2022Business WireStrong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million1 and consolidated cash, cash equivalents and short-term investments of $350.1 million,2 as of December 31,
- 3y agoAKLIAkili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ETBusiness WireAkili, Inc. (NASDAQ:AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the first quarter of 2023 on Thursday, May 11, 2023, at 4:30 p.m.
- 3y agoAKLIAkili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateBusiness WireEndeavorRxⓇ prescriptions increased 37% in Q4 2022 over Q3 2022 and 166% in FY 2022 over FY 2021; initial sales force gaining traction and Company is expanding to new U.S. territories Strong clinical data in
- 3y agoAKLIAkili to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, March 7 at 4:30 p.m. ETBusiness WireAkili, Inc. (NASDAQ:AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the fourth quarter and full year of 2022 on Tuesday, March 7, 2023
- 3y agoAKLIAkili to Participate in the Cowen 43rd Annual Health Care ConferenceBusiness WireAkili, Inc. (NASDAQ:AKLI), a leading digital medicine company, will participate in the Cowen 43rd Annual Health Care Conference in Boston next month. On March 8, Akili sessions are scheduled for the following
- 3y agoAKLIAkili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare ConferenceBusiness WireAkili, Inc. (NASDAQ:AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference, both happening alongside the J.P. Morgan Healthcare Conference in
- 3y agoAKLIPivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical OutcomesBusiness WireAttention improvements were nearly three times as large as those in the pivotal trial that served as the basis for EndeavorRx's FDA authorization for children with ADHD ages 8-12 Study data will be used to file for
- 3y agoAKLIBIIBGLSKRTX+2PureTech Provides End of Year Report on Key ProgressBusiness WireRapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and
- 3y agoAKLIAkili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical OfficerBusiness WireDr. Kollins brings decades of experience driving novel approaches to psychopharmacology and ADHD treatment Akili, Inc., a leading commercial digital medicine company, today announced the appointment of Scott Kollins,
- 4y agoAKLIAkili Reports Third Quarter 2022 Financial Results and Company UpdateBusiness WireEndeavorRx®, the world's first FDA-authorized video game treatment, saw quarter over quarter growth in number of prescribers and volume of prescriptions; Initiated commercial launch in Q3 Raised more than $164
- 4y agoAKLIFinancial Industry Veteran Mary Hentges Joins Akili's Board of DirectorsBusiness WireFormer chief financial officer at PayPal and CBS Interactive brings leadership experience spanning financial services, technology and healthcare industries Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company,
- 4y agoAKLIAkili to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 10 at 4:30 p.m. ETBusiness WireAkili, Inc. (NASDAQ:AKLI), a leading digital medicine company, will host a conference call and webcast to review its third quarter financial results on Thursday, November 10, 2022 at 4:30 p.m. ET. A live audio webcast
- 4y agoAKLIAkili Launches EndeavorRx® Expedition - A Direct-to-Patient Product RegistryBusiness WireThe fully remote registry is collecting real-world data from participants prescribed EndeavorRx® Akili Interactive ("Akili"), a leading digital medicine company, today announced the EndeavorRx® Expedition product registry, which aims to obtain feed
- 4y agoAKLIAkili to Participate in LifeSci Partners HealthTech SymposiumBusiness WireAkili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today announced that management will present at a fireside chat and participate in a panel discussion on prescription digital therapeutics at the virtual LifeSci Partners HealthTech Symposiu
- 4y agoAKLICPSRDNAAGLS+4PureTech Health plc – Half-Year ReportBusiness WireStrong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q
- 4y agoAKLIDNAADigital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. IBusiness WireAkili, Inc. common stock to begin trading on Nasdaq under the ticker symbol "AKLI" on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline